I am a PhD candidate at the Division of Drug Discovery and Safety (DDS), under the supervision of Prof. Dr. Bob van de Water and Dr. Peter Bouwman. My academic journey began with a Bachelor's in Pharmacy from Gujarat Technological University, India, followed by a Master of Science in Pharmacology from King's College London, UK. My research at King's delved into the relationship between nicotinamide adenine dinucleotide (NAD+) metabolism and synucleinopathies, particularly Parkinson's disease. Following my Masters, I immersed myself in the field of 3D organoids at the Hubrecht Organoid Technology (HUB), in the Netherlands. My expertise lies in the realm of stem cell and organoid technology, with a focus on tissue development in diseases. At HUB, I leveraged patient-derived organoids (PDO) for high-throughput compound screenings and employed CRISPR-Cas9 technology for mutagenesis modeling, identifying new therapeutic avenues. Currently, during my PhD, I aim to advance our understanding of non-genotoxic carcinogenicity, with a specific emphasis on the Mammary Gland. Through the integration of hiPSC-derived platforms, the lab's established reporter platform, and cutting-edge high-throughput imaging and transcriptomics techniques, I endeavor to unravel biological perturbations and uncover the underlying mechanisms.
- PARC (Partnership for the Assessment of Risks from Chemicals)
No relevant ancillary activities